1상모집 중

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

연구 개요

The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

스폰서
리드: 일라이 릴리
적응증
Overweight or Obesity, Healthy
중재
LY4064912, LY4064912, Placebo, Placebo
목표 등록
144
시작일
2025-08-28
완료(예정)
2026-11-01

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.